

FORM 7

MONTHLY PROGRESS REPORT – April 2024

Name of CSE Issuer: **1933 Industries Inc.**

Trading Symbol: **TGIF**

Number of Outstanding Listed Securities: **490,471,657**

Monthly Reporting Period – **April 2024**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CSE Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CSE.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CSE Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

1933 Industries is a Canadian-based, US operated cannabis consumer branded goods company with cultivation, extraction and manufacturing assets based in Las Vegas, Nevada. The Company operates under two subsidiaries: 91%-owned Alternative

Medicine Association (AMA), a licensed cannabis cultivator and producer in the state of Nevada; and 100%-owned Infused MFG (Infused), a manufacturer of wellness products. With a focus on the Nevada market, the Company wholesales its AMA and Level X branded premium flower and AMA line of concentrated cannabis products to legal dispensaries in the state. The Company also formulates and manufactures its own hemp-infused line of Canna Hemp™ and Canna Hemp X™ branded goods now sold across the United States.

2. Provide a general overview and discussion of the activities of management.

On April 2, 2024, the Company announced its unaudited interim consolidated financial statements for the three and six months ended January 31, 2024 and 2023 ("Q2 2024").

On April 8, 2024, the Company announced that its wholly owned subsidiary, FN Pharmaceuticals, has entered into a Membership Interest Purchase Agreement (the "Agreement") to acquire from the Company's Executive VP and General Counsel, Caleb Zobrist, his nine percent (9%) of the issued and outstanding membership interests of Alternative Medicine Association LC ("AMA"). Upon successful completion of this transaction, FN Pharmaceuticals would own 100% of the membership interest in AMA, the Company's cultivation and production subsidiary. Under the terms of the Agreement, the purchase price (the "Purchase Price") for the Membership is USD\$50,000, payable through the issuance of common shares of 1933 Industries (the "Shares"). The estimated number of Shares to be issued is 3,375,000 and the final number of shares will be determined by the 10-day VWAP price of the Shares prior to the closing date. The Shares will be issued to the seller via the Direct Registration System and will be subject to normal legends required by the US Securities and Exchange Commission and will be subject to four months and one day hold period required by applicable securities laws in Canada but will not be subject to escrow. The closing of this Agreement is conditional upon regulatory approvals, including the approval of the Canadian Securities Exchange, and the Nevada Cannabis Compliance Board, as applicable. There is no guarantee that this transaction will close.

As Mr. Zobrist is a senior officer of the Company, he is a "related party" to the Company within the meaning of Multilateral Instrument 61-101- Protection of Minority Security Holders in Special Transactions ("MI 61-101"). As such, the transaction constitutes a "related party transaction" within the meaning of MI 61-101.

The Company expects to rely on exemptions from formal valuation and the minority shareholder approval requirements of MI 61-101 found in sections 5.5(a) and 5.7(1)(a) of MI 61-101 as the fair market value of the transaction does not constitute more than the 25% of the Company's market capitalization.

3. Describe and provide details of any new products or services developed or offered.

- No new products or services were developed during April 2024.

4. **Describe and provide details of any products or services that were discontinued.**
 - No products were discontinued during April 2024. Canna Hemp products will continue to be sold until inventory is depleted.
5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**
 - No new relationships were formed during April 2024.
6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**
 - No contracts were terminated during April 2024.
7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**
 - No acquisitions were completed during April 2024.
8. **Describe the acquisition of new customers or loss of customers.**
 - Not Applicable.
9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**
 - Not applicable
10. **Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.**
 - Company-wide, there were 2 new hires and 4 terminations during the reporting period.
11. **Report on any labour disputes and resolutions of those disputes if applicable.**
 - Not applicable

- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

- Not applicable

- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

- Not applicable

- 14. Provide details of any securities issued and options or warrants granted.**

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

(1) State aggregate proceeds and intended allocation of proceeds.

- 15. Provide details of any loans to or by Related Persons.**

- Not applicable

- 16. Provide details of any changes in directors, officers or committee members**

- Not applicable

- 17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

- The Company continues to monitor the various cannabis-related bills introduced by the US government.
- The Department of Health and Human Services (HHS) recently recommended to the Drug Enforcement Administration (DEA) that marijuana be rescheduled from a Schedule I to Schedule III substance, as defined by the Controlled Substances Act. If implemented, the rescheduling would have a significant impact on cannabis companies as it would eliminate 280E taxation. This tax prohibits cannabis operators from deducting business expenses from gross income, leading to higher taxes than ordinary businesses are required to pay. The recommendation is encouraging to companies operating in the sector and the Company will continue to follow any developments closely, with the expectation that tax relief will have a positive benefit on the industry.
- As of January 1st, 2024, the Company will gain some relief as a change to the Nevada Wholesale Marijuana Tax (WMT) comes into effect, amending how companies are taxed under the fair market value calculation. Under existing law, the Department of Taxation determines the fair market value of wholesale cannabis and establishes a per pound rate, irrespective of the actual price of

the product sold to dispensaries. The Department of Taxation's FMV calculations have consistently overpriced actual market prices by 30-40%. The change means that the 15% tax will be calculated based on the actual sales price, resulting in significant cost savings for cultivators.

18. Certificate of Compliance

The undersigned hereby certifies that:

The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

1. As of the date hereof there was no material information concerning the Issuer which has not been publicly disclosed.
2. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
3. All the information in this Form 7 Monthly Progress Report is true.

Dated: May 3, 2024

Name of Director or Senior Officer

Marion McGrath

Signature

/s/ "Marion McGrath"

Official Capacity

Corporate Secretary

Issuer Details Name of Issuer	For Month End	Date of Report
1933 Industries Inc.	April 2024	May 3, 2024
Issuer Address 300 – 1055 West Hastings Street		
City/Province/Postal Code	Issuer phone	Issuer Fax No.
Vancouver, BC, V6E 2E9	604 674 4756	n/a
Contact Name	Contact Position	Contact Telephone No.
Marion McGrath	Corporate Secretary	604 684-6264
Contact Email Address mcgrath@iocorporate.com	Web Site Address http://1933industries.com/	